BeOne Medicines
Manufacturing · Switzerland · 10K+ Employees
View Company Info for Free
Overview
Headquarters
Aeschengraben 94 27, Basel, Basel-City, ...Phone Number
(781) 801-1800Website
www.beonemedicines.comRevenue
$5.7 BillionStock Symbol
BGNEIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
2
2
1
1
1
About BeOne Medicines
BeOne Medicines is a global biotechnology company focused on developing next-generation cancer treatments through innovative research and cutting-edge therapies. The company is committed to making these treatments accessible to patients worldwide, emphasizing speed, equity, and affordability in delivering care. Guided by the principle that cancer knows no borders, BeOne Medicines operates with a global perspective, striving to expand the reach of life-saving therapies and improve outcomes for patients everywhere.Explore more
BeOne Medicines Org Chart
MD
Global Senior VP, Clinical Operations
EZ
Vice PresidentHead of Hematology BU
ZS
Global Vice President, Head of Translational ...
SR
Vice President, Clinical Development Hematolo...
BJ
Vice President, Global Franchise Head - Hemat...
XS
Vice President & Head of Clinical Operations ...
NG
Global Vice President, Medical Affairs Solid ...
JH
Global Vice President, Clinical Development H...
AL
Vice President & Head of Greater , Global Cli...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BeOne Medicines your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if BeOne Medicines had a recent Job posting/layoffs
Earning: See what the market has to say on BeOne Medicines recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if BeOne Medicines has recently received funding, and reach out quickly before it becomes old news!
BeOne Medicines, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once BeOne Medicines has new funding data
Check out if BeOne Medicines is spiking on competitors!
Product Launch: Get notified when BeOne Medicines launches new products
Congratulate Masked Content for being promoted to Masked Content at BeOne Medicines
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at BeOne Medicines
Find 2 more new buyers
Compare CEO
How does John Oyler compare against Competing Companies' CEOs?
John Oyler
Founder & Chief Executive Officer at BeOne Me...
Top 50%
CEO management styleGood
100%Bad
0%VS.
William Lis
CEO at Portola Pharmaceuticals
CEO effectiveness to drive business results
Excellent
100%
Good
0%
Average
0%
Poor
0%
Very Bad
0%
Good
0%Bad
100%
Explore company insights
Get a deeper look into BeOne Medicines's structure, leadership, and market position:
Company Profile Activity
Activity Insights
BeOne Medicines is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BeOne Medicines is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BeOne Medicines.
BeOne Medicines financials insights
Gather financial insights about BeOne Medicines, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$75M
2015
Series B
$96.6M
2016
Stock Offering
$158M
Stock Offering
$200M
2020
Multiple Rounds
$4.2B
BeOne Medicines Tech Stack
A closer look at the technologies used by BeOne Medicines
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Open Position
Open Position
BeOne Medicines News & Media
BeOne Medicines (ONC) faces RMB 446m China tax settlement hit in Q2 - Stock Titan
BeOne Medicines settles a Chinese tax audit with an RMB 446m payment, to be recognized in Q2 fiscal 2026, highlighting ongoing exposure to complex foreign tax audits.BeOne Medicines AG (ONC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
BeOne Medicines AG (ONC) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 10:00 AM EDTCompany ParticipantsMark Lanasa - Senior VP...BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO Transcript
BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO June 1, 2026 8:01 PM EDTCompany ParticipantsLiza...BeOne Medicines AG (ONC) Q1 2026 Earnings Call Transcript
BeOne Medicines AG (ONC) Q1 2026 Earnings Call May 6, 2026 8:00 AM EDTCompany ParticipantsDaniel Maller - Vice President of Investor RelationsJohn Oyler -...
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding BeOne Medicines
Sign Up For FreeTo access detailed company insights
BeOne Medicines is a global biotechnology company focused on developing next-generation cancer treatments through innovative research and cutting-edge therapies. The company is committed to making these treatments accessible to patients worldwide, emphasizing speed, equity, and affordability in delivering care. Guided by the principle that cancer k... Read More
